Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Roy Cleeland"'
Publikováno v:
Antimicrobial Agents and Chemotherapy. 49:1468-1476
LBM415 (NVP PDF-713) is the first member of the peptide deformylase (PDF) inhibitor class being developed for clinical trials as a parenteral and oral agent for treatment of community-acquired respiratory tract disease and serious infections caused b
Autor:
Nathaniel M. Alpert, Edna Thom, Roy Cleeland, Robert H. Rubin, John W. Babich, Alan J. Fischman, Barbara Prosser, E. Livni, Yu-Ying Liu
Publikováno v:
International Journal of Antimicrobial Agents. 4:S15-S20
The delivery of fleroxacin, a new broad-spectrum fluoroquinolone, to the major organs of the body was studied in 12 normal human volunteers (nine men and three women), utilizing positron emission tomography (PET). Following the infusion of 20 mCi of
Autor:
Lorenzo Aguilar, M. Torrico, María-José Giménez, Luis Alou, David Sevillano, Roy Cleeland, Fabio Cafini, Natalia González, José Prieto
Publikováno v:
International Journal of Antimicrobial Agents
International Journal of Antimicrobial Agents, Elsevier, 2011, 37 (4), pp.332. ⟨10.1016/j.ijantimicag.2010.12.007⟩
International Journal of Antimicrobial Agents, Elsevier, 2011, 37 (4), pp.332. ⟨10.1016/j.ijantimicag.2010.12.007⟩
In order to determine whether reduced susceptibility or tolerance to vancomycin in Staphylococcus aureus influences the activity of daptomycin by simulating serum concentrations in the first 24h of treatment in the presence of physiological concentra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c5c4c0b396327414402832efa337116
https://hal.archives-ouvertes.fr/hal-00679606/document
https://hal.archives-ouvertes.fr/hal-00679606/document
Autor:
John A. Correia, Yu-Ying Liu, John W. Babich, Barbara Prosser, Fischman Alan J, E Thom, Roy Cleeland, H W Strauss, Eli Livni, Nathaniel M. Alpert
Publikováno v:
Antimicrobial Agents and Chemotherapy. 37:2144-2152
Positron emission tomography (PET) with [18F]fleroxacin was used to study the pharmacokinetics of fleroxacin, a new broad-spectrum fluoroquinolone, in 12 healthy volunteers (9 men and 3 women). The subjects were infused with a standard therapeutic do
Autor:
Robert H. Rubin, John W. Babich, Roy Cleeland, Nathaniel M. Alpert, Fischman Alan J, H. William Strauss, Eli Livni, Yu-Ying Liu, Edna Tham, John A. Correia, Barbara Prosser, Roland J. Callahan
Publikováno v:
The American Journal of Medicine. 94:31S-37S
A new method of tracing the disposition of fleroxacin was tested in infected and noninfected animals in an effort to develop a technique that might be applicable in humans. [18F]fleroxacin was synthesized and shown to be identical physically, chemica
Autor:
John A. Washington, William J. Novick, L. Barth Reller, Roy Cleeland, Clyde Thornsberry, Ronald N. Jones, Lauri Thrupp
Publikováno v:
Clinical Infectious Diseases. 15:S339-S346
This guideline summarizes recommendations for (1) developing cogent procedures for diagnosis and antimicrobial susceptibility testing; (2) developing quality-control parameters for the microbiological components of clinical trials; (3) continually up
Autor:
Fabio Cafini, Roy Cleeland, Giménez Mj, José Prieto Prieto, Natalia González, M. Torrico, Luis Alou, David Sevillano, Lorenzo Aguilar
Publikováno v:
International Journal of Antimicrobial Agents
International Journal of Antimicrobial Agents, Elsevier, 2009, 35 (2), pp.131. ⟨10.1016/j.ijantimicag.2009.09.021⟩
International Journal of Antimicrobial Agents, Elsevier, 2009, 35 (2), pp.131. ⟨10.1016/j.ijantimicag.2009.09.021⟩
This study explored the influence of vancomycin tolerance and protein binding on the bactericidal activity of vancomycin versus daptomycin (protein binding 36.9% vs. 91.7%, respectively) against four vancomycin-tolerant methicillin-resistant Staphylo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9101ae41850f8e82c540d001e31c2d93
https://hal.archives-ouvertes.fr/hal-00556371
https://hal.archives-ouvertes.fr/hal-00556371
Publikováno v:
Chemotherapy. 37:93-97
Ceftriaxone and amikacin were combined at ratios of 1:1, 5:1, and 10:1 and tested in vitro against Pseudomonas aeruginosa . The activity was determined using the Steers-Foltz replica
Autor:
A Specian, B Dix-Holzknecht, J. G. Christenson, H H Farrish, Chan Ka-Kong, Indravadan H. Patel, Roy Cleeland
Publikováno v:
Antimicrobial Agents and Chemotherapy. 34:1895-1900
Ro 23-9424 is a dual-action cephalosporin with an aminothiazolylmethoxyimino-type side chain at the 7 position and fleroxacin esterified at the 3' position. The new compound has broad and potent antibacterial activity in vitro and in vivo, reflecting
Autor:
Fischman Alan J, Barbara Prosser, Robert H. Rubin, Nathaniel M. Alpert, S Chodosh, John A. Correia, John W. Babich, P Kamitsuka, Ali A. Bonab, Roy Cleeland, Francis J. McGovern, Eli Livni, Yu-Ying Liu
The pharmacokinetics of fleroxacin, a new broad-spectrum fluoroquinolone, were measured by positron emission tomography (PET) with [18F]fleroxacin in five patients with acute bacterial exacerbations of chronic bronchitis and in five patients with sym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45659f869c0b882deb733654690caec6
https://europepmc.org/articles/PMC163176/
https://europepmc.org/articles/PMC163176/